Halozyme's HTI-101 enzyme effective against lung cancer in animal model

By Lisa Kerner

Charlotte, N.C., July 12 - Halozyme Therapeutics, Inc. said new findings in an animal model for HTI-101, its second hyaluronidase enzyme candidate, showed that increased blood levels of the HTI-101 enzyme were able to rescue mice with lung cancer and prolong their survival compared to those given control virus.

The study results were presented at the 2006 Gordon Research Conference on Proteoglycans.

"These findings are certainly intriguing, and warrant further investigation into the underlying mechanism of action of the enzyme in lung cancer, and could also lead to future studies with a recombinant human form," vice president and chief scientific officer Gregory Frost said in a company news release.

In the study, mice with one or both normal copies of the gene encoding HTI-101 showed significantly reduced or absent levels of enzyme in the blood.

When challenged with lung cancer, mice lacking the enzyme died up to 40% faster than those with two normal copies.

Andover, N.H.-based Halozyme is a biopharmaceutical company developing and commercializing recombinant human enzymes.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.